Treatment and prevention of intestinal graft-versus-host disease following HPSC transplantation
This technology is a method for enhancing intestinal barrier function for the prevention and treatment of graft-versus-host disease, which is often caused by allogeneic hematopoietic stem cell transplantation (HPSC).
Unmet Need: Prevention of stem cell transplantation-related complications
Allogeneic hematopoietic stem cell (HPSC) transplantation, a common therapy for various genetic diseases and cancers, often results in potentially fatal complications, such as graft-versus-host disease (GVHD). It is thought that GVHD arises from perturbations in the intestinal microbiota following allogeneic HPSC transplantation, leading to increased leukocyte activation characteristic of this complication. As such, a treatment that enhances intestinal resilience may prevent the onset of GVHD in transplant patients.
The Technology: GLP-2analogs for prevention and treatment of GVHD
This technology uses analogs of glucagon-like peptide 2 (GLP-2) to bolster intestinal barrier function in hematopoietic stem cell transplant recipients to protect against GVHD. Using a specified dosing schedule that promotes tissue repair, the proposed therapeutic regimen significantly reduces intestinal permeability that contributes to inflammation and GVHD onset. With few off-target effects and a low toxicity profile, this technology may be used in conjunction with existing therapeutic regimens to significantly reduce the incidence of GVHD in HPSC-transplant recipients.
This technology has been validated in mouse models of allogeneic HPSC transplantation.
Applications:
- Prevention and treatment of GVHD following HPSC transplantation
- Prevention of alloreactivity in solid organ transplants
- Treatment of toxicity after high-dose chemotherapy or radiation
- Therapies for autoimmune disorders of the gut (e.g. Crohn’s disease and ulcerative colitis)
Advantages:
- Reduces risk of GVHD following HPSC transplantation
- Promotes intestinal tissue repair
- May be used simultaneously with existing treatment regimens
- High specificity of drug mechanism
- Few off-target effects and low toxicity profile
Lead Inventor:
Patent Information:
Patent Pending (US20230364196)
Related Publications:
Tech Ventures Reference:
IR CU19098, CU23034, CU18125
Licensing Contact: Jerry Kokoshka